Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | LIG1 | P18858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019622 | 0.90 | HSP90AA1 (0.40) | HSP90AA1FLT3CASP1ADRB2ADRB1 | |
| SCHEMBL1019620 | 0.89 | FLT3 (0.43) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1019801 | 0.86 | TSHR (0.51) | HSP90AA1FLT3ADRB2ADRB1ADRB3 | |
| SCHEMBL1019663 | 0.84 | FLT3 (0.40) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1018764 | 0.82 | HSP90AA1 (0.44) | HSP90AA1GAATSHRTDP1MAPT | |
| SCHEMBL20393894 | 0.81 | FLT3 (0.50) | FLT3CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1018545 | 0.80 | HTT (0.48) | HSP90AA1KDM4EBLMGAATSHR | |
| SCHEMBL20391495 | 0.79 | TDP1 (0.49) | FLT3CASP1LIG1KDM4EBLM | |
| SCHEMBL1020983 | 0.78 | TSHR (0.48) | HSP90AA1FLT3ADRB2ADRB1ADRB3 | |
| SCHEMBL12765876 | 0.77 | LMNA (0.41) | ADRB2ADRB1KDM4EGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210820-A1 | Pharmaceutical Compounds | SLC10A1, MAPT, SLC5A1 | HSP90AA1 2662/4885FLT3 2313/4885CASP1 1008/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | HSP90AA1 4129/4885FLT3 3144/4885CASP1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.